Follistatin is an endogenous glycoprotein that binds and neutralises members of the TGF-beta superfamily, most notably myostatin, the principal negative regulator of skeletal muscle mass. FS-344 is one isoform.

The animal results are genuinely spectacular: follistatin overexpression produces large increases in muscle mass in mice and non-human primates. The human data for administering the protein is close to non-existent, and the small amount of human work that exists used gene therapy to induce local expression, not injection of a protein.

Conflating those two is the central error in how this compound is discussed.

Follistatin binds myostatin and activin with high affinity, preventing receptor engagement and removing the brake on muscle differentiation and growth.

Two practical problems sit between that and any effect from an injection. First, an injected protein of this size has a short circulating half-life and poor tissue distribution. Second, activin signalling is involved in far more than muscle, including reproductive endocrinology, inflammation and, importantly, tumour suppression in some tissues. Systemic myostatin and activin blockade is not a localised intervention.

Mechanistic and preclinical. Animal work with genetic overexpression and with gene-therapy delivery reports substantial increases in muscle mass and strength.

Human work is limited to small gene-therapy trials in muscular dystrophies, delivering a follistatin construct locally to muscle, with modest reported functional changes in very small numbers.

There is no controlled human evidence for administering follistatin protein for any purpose. Material sold as follistatin-344 is a research reagent of unverified identity, and the pharmacokinetic argument that an injected protein would even reach muscle in a meaningful concentration has not been made, let alone tested.

No human safety data for the administered protein at all.

The theoretical concerns follow directly from the mechanism. Activin signalling has tumour-suppressive roles in several tissues, and sustained systemic blockade of a growth-restraining pathway is exactly the kind of intervention that should have long-term oncological safety data before anyone considers it. It has none.

Effects on reproductive endocrinology are also plausible and uncharacterised.

Not approved anywhere. Research reagent. Myostatin-pathway drugs from pharmaceutical developers have repeatedly failed to show functional benefit in clinical trials despite increasing muscle mass, which is its own caution about the premise.